Ralph Niven, CHIEF SCIENTIFIC OFFICER at Aerovate Therapeutics, Inc. (AVTE), sold 2,250 shares at $17.23 ($39K) on 2023-07-05, disclosed to the SEC on 2023-07-07.
Scheduled sale ($39k) by CHIEF SCIENTIFIC OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.23 | 2,031 | $35K | 89.9% |
| 2 | $17.87 | 219 | $4K | 10.1% |
| Total | $17.29 avg | 2,250 | $39K | 100% |
| Filing → |
| AVTE | SELL | 2023-12-07 | $75K | — | Filing → |
| AVTE | SELL | 2023-11-27 | $207K | — | Filing → |
| AVTE | SELL | 2023-06-07 | $37K | — | Filing → |